Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

palonosetron

palonosetron
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Aloxi CAPSULE, ORAL 0.5 mg    
Aloxi SOLUTION, INTRAVENOUS 0.25 mg/5 mL    
VIEW MORE 5-HT3 Receptor Antagonists
CLASS
562220
Comments:

Palonosetron is restricted to use by oncology providers.

Palonosetron is interchangeable with ondansetron and granisetron for the prevention of CINV, with palonosetron as the workhorse agent when preferred by the NCCN and/or POGO guidelines.

 

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

 NOTES

palonosetron (Aloxi)

  • 0.25 mg IV
  • 0.5 mg PO

ondansetron (Zofran)

  • 16 mg
  • 16 mg PO (tablets, liquid or ODT)
  • Standardize ondansetron piggyback sol’n to 50 mL NS
  • ondansetron is a 1st line workhorse drug for palonosetron
  • Maximum ondansetron IV or PO dose is 16 mg

palonosetron (Aloxi)

  • 0.25 mg IV
  • 0.25 mg IV
  • 0.5 mg PO

granisetron (Kytril)

  • 1 mg IV
  • 2 mg PO
  • 2 mg PO

If patient unable to tolerate oral medication interchange to IV granisetron; interchange to granisetron if ondansetron not available

Interchange palonosetron to granisetron if ondansetron is in shortage/not available.

Reviewed: March 24, 2009 (Aloxi oral)

Updated: November 2024 (Palonosetron restrictions)

Palonosetron (ALOXI) SBAR Formulary Update.pdf 

Last updated: Dec. 24, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved